

DAFTAR PUSTAKA

- Abidin, R. M., Suwantika, A. A., & Pradipta, I. S. (2024). Cost Effectiveness Analysis of Oral Iron Chelating Drugs Between Deferiprone and Deferasirox in Thalassemia Major Patients At Bhayangkara Setukpa Lemdiklat Polri Tk.Ii Hospital. *Journal of Engineering, Social and Health*, 3(1), 173–185.
- Adramerina, A., & Economou, M. (2024). Challenges of Iron Chelation in Thalassemic Children. *Thalassemia Reports*, 14(1), 1–9. <https://doi.org/10.3390/thalassrep14010001>
- Akkol, E. K., & Aschner, M. (2022). An overview on metabolic disorders and current therapy. In *The Role of Phytonutrients in Metabolic Disorders* (pp. 3–33). Elsevier. <https://doi.org/10.1016/B978-0-12-824356-5.00004-7>
- Ali, S., Mumtaz, S., Shakir, H. A., Khan, M., Tahir, H. M., Mumtaz, S., Mughal, T. A., Hassan, A., Kazmi, S. A. R., Sadia, Irfan, M., & Khan, M. A. (2021). Current status of beta-thalassemia and its treatment strategies. *Molecular Genetics & Genomic Medicine*, 9(12). <https://doi.org/10.1002/mgg3.1788>
- Alkinani, A. A. (2017). AN Epidemiological Study of Thalassaemia Patients Attending Thalassaemic Center in Wassit Governorate. *World Journal of Pharmaceutical Research*, 1–12. <https://doi.org/10.20959/wjpr201710-8949>
- Ansari, S. H., & Hussain, Z. (2018). An Insight into the Symptomatology of β -Thalassaemia Major: Molecular Genetic Basis of the Disease – III. *National Journal of Health Sciences*, 3(1), 1–2. <https://doi.org/10.21089/njhs.31.0001>
- Asadov, C., Alimirzoeva, Z., Mammadova, T., Aliyeva, G., Gafarova, S., & Mammadov, J. (2018). β -Thalassemia intermedia: a comprehensive overview and novel approaches. *International Journal of Hematology*, 108(1), 5–21. <https://doi.org/10.1007/s12185-018-2411-9>
- Bellis, G., & Parant, A. (2022). Beta-thalassemia in Mediterranean countries. Findings and outlook. *Investigaciones Geográficas*, 77, 129. <https://doi.org/10.14198/INGEO.19079>
- Botzenhardt, S., Li, N., Chan, E. W., Sing, C. W., Wong, I. C. K., & Neubert, A. (2017). Safety profiles of iron chelators in young patients with haemoglobinopathies. *European Journal of Haematology*, 98(3), 198–217. <https://doi.org/10.1111/ejh.12833>
- Cappellini, M.-D., Cohen, A., Eleftheriou, A., Piga, A., Porter, J., & Taher, A. (2008). *Guidelines for the Clinical Management of Thalassaemia* (2nd Revise). Thalassaemia International Federation.
- Cappellini, M. D. (2006). A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. *Blood*, 107(9), 3455–3462. <https://doi.org/10.1182/blood-2005-08-3430>
- Cappellini, M. D., Bejaoui, M., & Agaoglu, L. (2011). Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy

- and safety during 5 years' follow-up (Blood (2011) 118, 4 (884-893)). *Blood*, 118(18), 5060. <https://doi.org/10.1182/blood-2011-09-377929>
- Ding, J., Huang, Z., Jiang, X., Li, Q., Cao, Y., & Guo, Y. (2022). The prevalence and genetic disorders spectrum of thalassemia among breast cancer patients in Jiangxi province, China. *Frontiers in Genetics*, 13. <https://doi.org/10.3389/fgene.2022.1001369>
- Elsayed, L. ., & Abd El-Gawad, S. . (2015). Nursing guidelines for children suffering from betathalassemia. *International Journal of Nursing Science*, 5(4), 131–135.
- Faizan, M., Rashid, N., Hussain, S., Khan, A., Khan, J., Zeb, S., & Ahmed, S. Q. (2023). Prevalence and Clinical Features of Thalassemia Minor Cases. *Pakistan Journal of Medical and Health Sciences*, 17(2), 456–459. <https://doi.org/10.53350/pjmhs2023172456>
- Garcia-Casal, M. N., Pasricha, S.-R., Martinez, R. X., Lopez-Perez, L., & Peña-Rosas, J. P. (2021). Serum or plasma ferritin concentration as an index of iron deficiency and overload. *Cochrane Database of Systematic Reviews*, 2021(5). <https://doi.org/10.1002/14651858.CD011817.pub2>
- Hay, D., & Weatherall, D. J. (2017). Thalassaemias. In *Encyclopedia of Life Sciences* (pp. 1–6). Wiley. <https://doi.org/10.1002/9780470015902.a0002274.pub3>
- Hoffbrand, A. V., Taher, A., & Cappellini, M. D. (2012). How I treat transfusional iron overload. *Blood, The Journal of the American Society of Hematology*, 120(18), 3657–3669.
- Jha, R., & Jha, S. (2014). Beta thalassemia - a review. *Journal of Pathology of Nepal*, 4(8), 663–671. <https://doi.org/10.3126/jpn.v4i8.11609>
- Kababi, S. El, Khalfi, B. El, Maani, K. El, & Soukri, A. (2020). Beta Thalassemia Major: Overview of Molecular Etiology, Pathophysiology, Current and Novel Therapeutic Approaches. *International Blood Research & Reviews*, 1–15. <https://doi.org/10.9734/ibrr/2019/v10i230118>
- Kattamis, A., Forni, G. L., Aydinok, Y., & Viprakasit, V. (2020). Changing patterns in the epidemiology of β -thalassemia. *European Journal of Haematology*, 105(6), 692–703. <https://doi.org/10.1111/ejh.13512>
- Kemenkes RI. (2018). *Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/1/2018 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Thalassemia*.
- Lee, J.-S., Rhee, T.-M., Jeon, K., Cho, Y., Lee, S.-W., Han, K.-D., Seong, M.-W., Park, S.-S., & Lee, Y. K. (2022). Epidemiologic Trends of Thalassemia, 2006–2018: A Nationwide Population-Based Study. *Journal of Clinical Medicine*, 11(9), 2289. <https://doi.org/10.3390/jcm11092289>
- Maggio, A., Kattamis, A., Felisi, M., Reggiardo, G., El-Beshlawy, A., Bejaoui, M., Sherief, L., Christou, S., Cosmi, C., Della Pasqua, O., Del Vecchio, G. C.,

- Filosa, A., Cuccia, L., Hassab, H., Kreka, M., Origa, R., Putti, M. C., Spino, M., Telfer, P., ... Ceci, A. (2020). Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. *The Lancet Haematology*, 7(6), e469–e478. [https://doi.org/10.1016/S2352-3026\(20\)30100-9](https://doi.org/10.1016/S2352-3026(20)30100-9)
- Musallam, K. M., Lombard, L., Kistler, K. D., Arregui, M., Gilroy, K. S., Chamberlain, C., Zagadailov, E., Ruiz, K., & Taher, A. T. (2023). Epidemiology of clinically significant forms of alpha- and beta-thalassemia: A global map of evidence and gaps. *American Journal of Hematology*, 98(9), 1436–1451. <https://doi.org/10.1002/ajh.27006>
- Nurbahiyah, E., & Maulina, D. (2023). Profil Penggunaan Obat Kelasi Besi Pada Pasien Talasemia Poli Anak Di Rumah Sakit X Jatinegara. *Indonesian Journal of Health Science*, 3(2), 149–154. <https://doi.org/10.54957/ijhs.v3i2.441>
- Nurhasanah, L. (2024). *Kajian Penggunaan Obat Kelasi Besi pada Pasien Talasemia Mayor di RSUD dr. Soedirman Kebumen pada Periode Tahun 2023*.
- Nurhasanah, L., Ainni, A. N., Widiastuti, T. C., & Khuluq, M. H. (2025). Kajian Penggunaan Obat Kelasi Besi Pada Pasien Talasemia Mayor Di Rsud X Kebumen Tahun 2023. *Usadha: Journal of Pharmacy*, 4(1), 116–123.
- Origa, R. (2017). β -Thalassemia. *Genetics in Medicine*, 19(6), 609–619. <https://doi.org/10.1038/gim.2016.173>
- Putri, R. A., & Handayani, H. (2018). Gambaran Karakteristik Penderita Talasemia Mayor di RSUD Dr. Moewardi Surakarta Tahun 2015–2017. *Jurnal Kesehatan*, 9(1), 45–52.
- Rahmawati, D., Hidayati, S., & Siregar, F. A. (2020). Karakteristik Anak dengan Talasemia Mayor di RSUP H. Adam Malik Medan. *Jurnal Ilmu Dan Teknologi Kesehatan*, 8(1), 30–36.
- Rejeki, D. S. S., Nurhayati, N., Supriyanto, S., & Kartikasari, E. (2012). Studi Epidemiologi Deskriptif Talasemia. *Kesmas: National Public Health Journal*, 7(3), 139. <https://doi.org/10.21109/kesmas.v7i3.61>
- Sadiq, I. Z., Abubakar, F. S., Usman, H. S., Abdullahi, A. D., Ibrahim, B., Kastayal, B. S., Ibrahim, M., & Hassan, H. A. (2024). Thalassaemia: Pathophysiology, Diagnosis, and Advances in Treatment. *Thalassaemia Reports*, 14(4), 81–102. <https://doi.org/10.3390/thalassrep14040010>
- Sari, M. E., Widodo, D. W., & Prasetyo, D. (2021). Analisis Data Talasemia Mayor Anak di RSUP Dr. Sardjito Yogyakarta. *Jurnal Kedokteran Anak Indonesia*, 3(2), 112–118.
- Shafique, F., Ali, S., Almansouri, T., Van Eeden, F., Shafi, N., Khalid, M., Khawaja, S., Andleeb, S., & Hassan, M. ul. (2023). Thalassaemia, a human blood disorder. *Brazilian Journal of Biology*, 83. <https://doi.org/10.1590/1519-6984.246062>

- Singh, N., Hira, J. K., Chhabra, S., Das, R., Khadwal, A. R., & Sharma, P. (2023). β -thalassemia intermedia mimicking β -thalassemia trait: The importance of family studies and HBB genotyping in phenotypically ambiguous cases. *International Journal of Laboratory Hematology*, 45(4), 609–612. <https://doi.org/10.1111/ijlh.14047>
- Supriatna, C., Indriani, B. K., & Akbari, R. (2020). Evaluasi Penggunaan Obat Kelasi Besi Dalam Menurunkan Kadar Ferritin Pada Pasien Talasemia Anak di RSUD 45 Kuningan. *Syntax Literate ; Jurnal Ilmiah Indonesia*, 5(1), 28. <https://doi.org/10.36418/syntax-literate.v5i1.854>
- Suyitno, S. (2019). Faktor Risiko dan Distribusi Jenis Kelamin pada Pasien Talasemia Mayor di Indonesia. *Jurnal Biomedik*, 11(2), 85–90.
- Tanzani, A. M. (2019). Kajian Penggunaan Obat Kelasi Besi Pada Pasien Talasemia Anak-Anak Di Salah Satu Rumah Sakit Kuningan. In *Skripsi* (Vol. 1, Issue 1).
- Tarım, H. Ş., & Öz, F. (2022). Thalassaemia Major and Associated Psychosocial Problems: A Narrative Review. *Iranian Journal of Public Health*. <https://doi.org/10.18502/ijph.v51i1.8287>
- Triwardhani, E. R., Reniarti, L., & Setiabudiawan, B. (2022). Hubungan Jenis dan Tingkat Kepatuhan Pengobatan Kelasi Besi Oral dengan Kadar Feritin Serum pada Penyandang Talasemia Beta Mayor Anak. *Sari Pediatri*, 24(1), 23. <https://doi.org/10.14238/sp24.1.2022.23-30>